Jacob Pfaller v. Mark Amonette

55 F.4th 436
CourtCourt of Appeals for the Fourth Circuit
DecidedDecember 15, 2022
Docket21-1555
StatusPublished
Cited by55 cases

This text of 55 F.4th 436 (Jacob Pfaller v. Mark Amonette) is published on Counsel Stack Legal Research, covering Court of Appeals for the Fourth Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Jacob Pfaller v. Mark Amonette, 55 F.4th 436 (4th Cir. 2022).

Opinion

USCA4 Appeal: 21-1555 Doc: 84 Filed: 12/15/2022 Pg: 1 of 52

PUBLISHED

UNITED STATES COURT OF APPEALS FOR THE FOURTH CIRCUIT

No. 21-1555

JACOB PFALLER, Administrator of the Estate of Danny Harold Pfaller,

Plaintiff - Appellee,

v.

DR. MARK AMONETTE, in his individual capacity,

Defendant - Appellant,

and

DR. LAURENCE SHU-CHUNG WANG, in his individual capacity,

Defendant.

------------------------------

RIGHTS BEHIND BARS,

Amicus Supporting Appellee.

No. 21-1612

JACOB PFALLER, Administrator of the Estate of Danny Harold Pfaller,

DR. LAURENCE SHU-CHUNG WANG, in his individual capacity, USCA4 Appeal: 21-1555 Doc: 84 Filed: 12/15/2022 Pg: 2 of 52

Appeal from the United States District Court for the Eastern District of Virginia, at Richmond. Robert E. Payne, Senior District Judge. (3:19-cv-00728-REP)

Argued: September 16, 2022 Decided: December 15, 2022

Before WILKINSON, WYNN, and DIAZ, Circuit Judges.

Affirmed in part, reversed in part, and remanded by published opinion. Judge Wynn wrote the opinion, in which Judge Diaz joined. Judge Wilkinson wrote a separate opinion concurring in part and dissenting in part.

ARGUED: Andrew Nathan Ferguson, Erika L. Maley, OFFICE OF THE ATTORNEY GENERAL OF VIRGINIA, Richmond, Virginia, for Appellants. John Michael Shoreman, MCFADDEN & SHOREMAN, Washington, D.C., for Appellee. ON BRIEF: Mark R. Herring, Attorney General, K. Scott Miles, Deputy Attorney General, Laura Maughan, Assistant Attorney General, Michelle S. Kallen, Acting Solicitor General, Brittany M. Jones, Deputy Solicitor General, Laura H. Cahill, Assistant Attorney General, Rohiniyurie Tashima, John Marshall Fellow, OFFICE OF THE ATTORNEY GENERAL OF VIRGINIA, Richmond, Virginia, for Appellant Dr. Amonette. Erin B. Ashwell, Chief Deputy Attorney General, A. Anne Lloyd, Assistant Attorney General, OFFICE OF THE ATTORNEY GENERAL OF VIRGINIA, Richmond, Virginia; Lynne Jones Blain, M. Scott Fisher, Jr., HARMAN CLAYTOR CORRIGAN WELLMAN, Glen Allen, Virginia, for Appellant Dr. Wang. Mario B. Williams, Dallas S. LePierre, HDR LLC, Atlanta,

2 USCA4 Appeal: 21-1555 Doc: 84 Filed: 12/15/2022 Pg: 3 of 52

Georgia, for Appellee. Oren Nimmi, RIGHTS BEHIND BARS, Washington, D.C., for Amicus Rights Behind Bars.

3 USCA4 Appeal: 21-1555 Doc: 84 Filed: 12/15/2022 Pg: 4 of 52

WYNN, Circuit Judge:

Danny Pfaller died from liver cancer while he was a prisoner with the Virginia

Department of Corrections (“Department”). His estate sued several prison officials under

42 U.S.C. § 1983 and Virginia law, alleging that they violated the Eighth Amendment and

state law by failing to provide Pfaller treatment for his chronic hepatitis C until it was too

late.

Defendants in this appeal are Dr. Mark Amonette and Dr. Laurence Shu-Chung

Wang. Plaintiff alleges that Dr. Amonette designed treatment guidelines for inmates with

hepatitis C that unconstitutionally excluded Pfaller from receiving treatment. Plaintiff also

alleges that Dr. Wang failed to follow those guidelines and committed both medical

malpractice and Eighth Amendment violations in denying him appropriate treatment.

Defendants unsuccessfully moved for summary judgment, alleging that they were

protected by qualified immunity and, on Dr. Wang’s part, derivative sovereign immunity.

For the reasons that follow, we reverse the district court’s denial of sovereign

immunity to Dr. Wang and denial of qualified immunity to Dr. Amonette but affirm its

denial of qualified immunity to Dr. Wang.

I.

Because this case is before us on interlocutory appeal, the following facts are

recounted as the district court viewed them, and in the light most favorable to Pfaller. See

Hicks v. Ferreyra, 965 F.3d 302, 305 (4th Cir. 2020).

4 USCA4 Appeal: 21-1555 Doc: 84 Filed: 12/15/2022 Pg: 5 of 52

A.

Hepatitis C is a disease caused by a viral infection of the liver. In certain individuals,

hepatitis C can persist as an asymptomatic infection for years. In others, the virus can lead

to liver inflammation, fibrosis (liver scarring), cirrhosis (liver tissue death), and even

terminal liver cancer.

For many years, the only curative treatment for hepatitis C was a course of

interferon-based drugs. However, these drugs offered a low cure rate (40 to 50%) and

caused major side effects, including life-threatening neuropsychiatric and autoimmune

disorders. In 2014, the Food and Drug Administration began approving a suite of new drugs

called direct-acting antivirals for treatment of hepatitis C patients. These drugs offered

great promise. Not only were they less likely to cause serious side effects, but they also

boasted cure rates of 90 to 100%. By 2015, direct-acting antivirals were available for

treating hepatitis C patients.

In response to these medical advances, Dr. Amonette, the Department’s chief

physician, developed new hepatitis C treatment guidelines (“Guidelines”) for the

Department. Under the Guidelines, the Department agreed to refer inmates with hepatitis

C to a clinic at Virginia Commonwealth University (“VCU”) based on certain criteria.

These criteria sorted inmates into three groups based on APRI and FIB-4 scores that

assessed their level of fibrosis (if any). 1 Inmates who scored at the high end of the scale

1 “APRI” stands for “aspartate aminotransferase to platelet ratio.” J.A. 116. It is a noninvasive way to estimate fibrosis, or liver scarring. J.A. 397. “FIB-4” is short for “Fibrosis-4 index,” and is another formula used to assess fibrosis based on a patient’s age,

5 USCA4 Appeal: 21-1555 Doc: 84 Filed: 12/15/2022 Pg: 6 of 52

were to be “automatically referred to VCU for evaluation without any additional testing.”

J.A. 116. Inmates who scored in the middle tier were to receive “additional testing to

determine whether [they] should be referred for evaluation.” Id. And those who scored at

the low end were not to be referred for treatment and instead were to “receive periodic

laboratory blood testing and chronic care appointments with a medical provider.” Id.

Outside of these criteria, a physician could also refer an inmate to the VCU clinic “if there

[were] other findings suggestive of advanced liver disease.” J.A. 303. Once referred, the

inmate would receive an antiviral prescription unless there was some other medical reason

not to treat them.

Dr. Amonette explains that these Guidelines were designed to ensure that those with

the greatest need were treated first. Plaintiff’s expert disputes this, stating that the

Guidelines were actually a tool for excluding patients from treatment. The parties agree

that when resources are limited, prioritization of patients with the most advanced disease

can be a reasonable strategy. But whether the Department’s resources were actually limited

is disputed.

B.

Danny Pfaller was an inmate with the Department from 1999 to 2018. As early as

2007, Pfaller tested positive for hepatitis C. Beginning in 2015, Pfaller had his blood drawn

platelet count, and other factors. J.A. 116, 397. Citations to the “J.A.” refer to the parties’ Joint Appendix filed in this appeal.

6 USCA4 Appeal: 21-1555 Doc: 84 Filed: 12/15/2022 Pg: 7 of 52

every six to twelve months to assess his APRI and FIB-4 scores, consistent with the

Guidelines. During this time, Dr. Wang served as Pfaller’s primary physician.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
55 F.4th 436, Counsel Stack Legal Research, https://law.counselstack.com/opinion/jacob-pfaller-v-mark-amonette-ca4-2022.